Terms: = Kidney tumors AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987 AND Treatment
28 results:
1. Molecular imaging and treatment of PSMA-positive prostate cancer with
Jiao Y; Xu P; Luan S; Wang X; Gao Y; Zhao C; Fu P
Nucl Med Biol; 2022; 104-105():28-37. PubMed ID: 34847481
[TBL] [Abstract] [Full Text] [Related]
2. kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, mdm2, MDM4, p53, KRAS and AKT in renal cell carcinoma.
Li F; Aljahdali IAM; Zhang R; Nastiuk KL; Krolewski JJ; Ling X
J Exp Clin Cancer Res; 2021 Aug; 40(1):254. PubMed ID: 34384473
[TBL] [Abstract] [Full Text] [Related]
3. Recent Advances in Pathology: the 2021 Annual Review Issue of The Journal of Pathology.
Herrington CS; Poulsom R; Koeppen H; Coates PJ
J Pathol; 2021 Jul; 254(4):303-306. PubMed ID: 34097314
[TBL] [Abstract] [Full Text] [Related]
4. Effect of murine double-minute 2 inhibitors in preclinical models of advanced clear cell carcinomas originating from ovaries and kidneys.
Kawata Y; Nagasaka K; Oda K; Makii C; Takeuchi M; Oki S; Honjo H; Kojima M; Miyagawa Y; Taguchi A; Tanikawa M; Sone K; Hiraike H; Matsumoto Y; Wada-Hiraike O; Ayabe T; Osuga Y; Fujii T
Cancer Sci; 2020 Oct; 111(10):3824-3834. PubMed ID: 32713096
[TBL] [Abstract] [Full Text] [Related]
5. β-Sitosterol Reverses Multidrug Resistance via BCRP Suppression by Inhibiting the p53-mdm2 Interaction in Colorectal Cancer.
Wang Z; Zhan Y; Xu J; Wang Y; Sun M; Chen J; Liang T; Wu L; Xu K
J Agric Food Chem; 2020 Mar; 68(12):3850-3858. PubMed ID: 32167760
[TBL] [Abstract] [Full Text] [Related]
6. Sesamin suppresses NSCLC cell proliferation and induces apoptosis via Akt/p53 pathway.
Chen Y; Li H; Zhang W; Qi W; Lu C; Huang H; Yang Z; Liu B; Zhang L
Toxicol Appl Pharmacol; 2020 Jan; 387():114848. PubMed ID: 31809756
[TBL] [Abstract] [Full Text] [Related]
7. Brain Distributional Kinetics of a Novel mdm2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy.
Kim M; Laramy JK; Gampa G; Parrish KE; Brundage R; Sarkaria JN; Elmquist WF
Drug Metab Dispos; 2019 Dec; 47(12):1403-1414. PubMed ID: 31619389
[TBL] [Abstract] [Full Text] [Related]
8. Molecular pathways related to the control of proliferation and cell death in 786-O cells treated with plumbagin.
Mancilla IA; Coatti GC; Biazi BI; Zanetti TA; Baranoski A; Marques LA; Corveloni AC; Lepri SR; Mantovani MS
Mol Biol Rep; 2019 Dec; 46(6):6071-6078. PubMed ID: 31456160
[TBL] [Abstract] [Full Text] [Related]
9. Muscle wasting in patients with end-stage renal disease or early-stage lung cancer: common mechanisms at work.
Aniort J; Stella A; Philipponnet C; Poyet A; Polge C; Claustre A; Combaret L; Béchet D; Attaix D; Boisgard S; Filaire M; Rosset E; Burlet-Schiltz O; Heng AE; Taillandier D
J Cachexia Sarcopenia Muscle; 2019 Apr; 10(2):323-337. PubMed ID: 30697967
[TBL] [Abstract] [Full Text] [Related]
10. mdm2 inhibitor ameliorates cisplatin-induced nephropathy via NFκΒ signal inhibition.
Fujikura T; Yasuda H; Iwakura T; Tsuji T; Anders HJ
Pharmacol Res Perspect; 2019 Feb; 7(1):e00450. PubMed ID: 30564368
[TBL] [Abstract] [Full Text] [Related]
11. Isoliquiritigenin inhibits the proliferation of human renal carcinoma Caki cells through the ROS-mediated regulation of the Jak2/STAT3 pathway.
Kim DH; Park JE; Chae IG; Park G; Lee S; Chun KS
Oncol Rep; 2017 Jul; 38(1):575-583. PubMed ID: 28560439
[TBL] [Abstract] [Full Text] [Related]
12. Inhibition of mdm2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53.
Tian X; Dai S; Sun J; Jiang S; Sui C; Meng F; Li Y; Fu L; Jiang T; Wang Y; Su J; Jiang Y
Cell Physiol Biochem; 2016; 39(5):2088-2098. PubMed ID: 27825169
[TBL] [Abstract] [Full Text] [Related]
13. Selective effects of a fiber chimeric conditionally replicative adenovirus armed with hep27 gene on renal cancer cell.
Fang L; Cheng Q; Liu W; Zhang J; Ge Y; Zhang Q; Li L; Liu J; Zheng J
Cancer Biol Ther; 2016 Jun; 17(6):664-73. PubMed ID: 27195521
[TBL] [Abstract] [Full Text] [Related]
14. The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation.
Du Z; Li L; Huang X; Jin J; Huang S; Zhang Q; Tao Q
Oncotarget; 2016 Apr; 7(16):21618-30. PubMed ID: 26943038
[TBL] [Abstract] [Full Text] [Related]
15. Carnosic acid induces apoptosis through inactivation of Src/STAT3 signaling pathway in human renal carcinoma Caki cells.
Park JE; Park B; Chae IG; Kim DH; Kundu J; Kundu JK; Chun KS
Oncol Rep; 2016 May; 35(5):2723-32. PubMed ID: 26936454
[TBL] [Abstract] [Full Text] [Related]
16. Low expression of phosphatase and tensin homolog in clear‑cell renal cell carcinoma contributes to chemoresistance through activating the Akt/hdm2 signaling pathway.
Chen J; Zhu H; Zhang Y; Cui MH; Han LY; Jia ZH; Wang L; Teng H; Miao LN
Mol Med Rep; 2015 Aug; 12(2):2622-8. PubMed ID: 25954860
[TBL] [Abstract] [Full Text] [Related]
17. Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma.
Joshi S; Singh AR; Durden DL
Cancer Chemother Pharmacol; 2015 Mar; 75(3):595-608. PubMed ID: 25578041
[TBL] [Abstract] [Full Text] [Related]
18. New agents and new targets for renal cell carcinoma.
Philips GK; Atkins MB
Am Soc Clin Oncol Educ Book; 2014; ():e222-7. PubMed ID: 24857106
[TBL] [Abstract] [Full Text] [Related]
19. The von Hippel-Lindau tumor suppressor regulates programmed cell death 5-mediated degradation of mdm2.
Essers PB; Klasson TD; Pereboom TC; Mans DA; Nicastro M; Boldt K; Giles RH; MacInnes AW
Oncogene; 2015 Feb; 34(6):771-9. PubMed ID: 24469044
[TBL] [Abstract] [Full Text] [Related]
20. Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review.
Bizzarri M; Proietti S; Cucina A; Reiter RJ
Expert Opin Ther Targets; 2013 Dec; 17(12):1483-96. PubMed ID: 24032643
[TBL] [Abstract] [Full Text] [Related]
[Next]
